CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Corp. (NASDAQ: DYAX), a developer of novel biotherapeutics for unmet
medical needs, announced today that Gustav A. Christensen, President and
Chief Executive Officer of Dyax, will present at the Deutsche Bank 36th
Annual Health Care Conference, being held May 2-4 2011 at the
InterContinental Hotel in Boston, MA. Mr. Christensen will provide a
corporate update regarding the Company's three major business franchises
and value drivers - KALBITOR® (ecallantide), the Licensing
and Funded Research Program (LFRP) and the internal pipeline, including
label expansion efforts with KALBITOR. The Dyax presentation is
scheduled for Monday, May 2 at 10:00 AM ET.
The Dyax presentation will be webcast live and may be accessed by
visiting the Investor Relations section of the company website at www.dyax.com.
The webcast will also be available on the Dyax website for a limited
period of time following the conference.
Dyax is a fully integrated biopharmaceutical company focused on
discovering, developing and commercializing novel biotherapeutics for
unmet medical needs. The Company's lead product, ecallantide, has been
approved under the brand name KALBITOR® in the United States
for the treatment of acute attacks of hereditary angioedema (HAE) in
patients 16 years of age and older.
Dyax is commercializing KALBITOR in the United States independently, and
establishing strategic partnerships to develop and commercialize
ecallantide for the treatment of HAE in key regions worldwide.
Currently, Dyax has partnership agreements for regions including Europe,
Japan, Russia, the Middle East, Israel, North Africa, Australia and New
Zealand. The company is also exploring other potential indications for
ecallantide, either alone or through partnerships, including
drug-induced angioedema and retinal vein occlusion-induced macular edema.
Ecallantide and other compounds in Dyax's pipeline were identified using
its patented phage display technology, which rapidly selects compounds
that bind with high affinity and specificity to therapeutic targets.
Dyax leverages this technology broadly through the LFRP, which has
approximately 75 revenue generating licenses and collaborations for
therapeutic discovery, as well as for affinity separations, diagnostic
imaging, and research reagents. The success of the Company's LFRP
royalty portfolio is illustrated by the program's advanced licensee
pipeline that includes 17 candidates in clinical development. Of those
candidates, four are in Phase 3 clinical trials, four are in Phase 2 and
nine are in Phase 1.
Nicole Jones, 617-250-5744
Relations and Corporate Communications
Source: Dyax Corp.
News Provided by Acquire Media